Artal Group S.A. Syndax Pharmaceuticals Inc Transaction History

Artal Group S.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 09, 2018	SELL	$6.33 - $8.08 $384,212 - $490,431	-60,697 Closed	0 $0
Q2 2018 Aug 10, 2018	SELL	$6.93 - $14.63 $618,869 - $1.31 Million	-89,303 Reduced 59.54%	60,697 $426,000
Q4 2017 Feb 09, 2018	SELL	$7.8 - $12.94 $22,776 - $37,784	-2,920 Reduced 1.91%	150,000 $1.31 Million
Q3 2017 Nov 08, 2017	BUY	$10.9 - $12.73 $1.67 Million - $1.95 Million	152,920	152,920 $1.79 Million

228

88.4M

1.01M

692K

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $749M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.